secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001641172-25-015522
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir Pharmaceuticals announces positive preclinical data for Telomir-1 in progeria cell lines
--------------------------------------------------------------------------------

- Telomir-1 significantly increased cell viability in human HGPS cells under basal and metal-toxic conditions.
- Telomir-1 normalized reactive oxygen species (ROS) levels in Progeria cells, reducing oxidative stress.
- Telomir-1 reversed calcium overload, restoring mitochondrial function and energy balance.
- Company is finalizing IND-enabling studies and plans to engage FDA for orphan drug designation.
- Data builds on prior Telomir-1 results in Werner syndrome models (zebrafish, C. elegans) showing lifespan extension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225015522/0001641172-25-015522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225015522/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-015522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer